Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30128237 | 0.83 | MAOA (0.36) | BACE1MAOAMAOB | |
| SCHEMBL247196 | 0.82 | BACE1 (0.42) | BACE1POLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3267392 | 0.79 | RAB9A (0.40) | BACE1SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL13143422 | 0.79 | BACE1 (0.47) | BACE1POLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL5153339 | 0.78 | MAOA (0.61) | RAB9AALDH1A1MAOAMAOBCYP3A4 | |
| SCHEMBL10509506 | 0.78 | MTNR1A (0.46) | ALDH1A1MAOAMAOBTDP1L3MBTL1 | |
| SCHEMBL8817290 | 0.76 | BACE1 (0.53) | BACE1POLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL19740577 | 0.75 | TDP1 (0.34) | ALDH1A1MAOAMAOBTDP1LMNA | |
| SCHEMBL2069242 | 0.74 | KIF11 (0.47) | BACE1POLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL19740336 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283478-B2 | Process for preparation of sulfamide derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-09 | — | — | US | disclosed |
| CN-101090896-B | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | JANSSEN PHARMACEUTICA NV | 2011-10-26 | — | — | CN | disclosed |
| CN-101754947-A | The preparation method of sulfone amide derivative | JANSSEN PHARMACEUTICA NV | 2010-06-23 | — | — | CN | disclosed |
| EP-1794143-B8 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-24 | — | — | EP | disclosed |
| EP-1794143-B1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1881959-A1 | PROCESS FOR PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-30 | — | — | EP | disclosed |
| US-20070293476-A1 | CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | SMITH-SWINTOSKY VIRGINIA L | 2007-12-20 | — | — | US | disclosed |
| CN-101090896-A | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-19 | — | — | CN | disclosed |
| WO-2007137164-A2 | CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007095606-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191459-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191453-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | disclosed |
| US-20070191451-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | disclosed |
| US-20070191452-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | disclosed |
| EP-1794143-A1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-20060276528-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | ABDEL-MAGID AHMED F | 2006-12-07 | — | — | US | disclosed |
| US-20060270856-A1 | Process for preparation of sulfamide derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-30 | — | — | US | disclosed |
| WO-2006127184-A1 | PROCESS FOR PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006023861-A1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-02 | — | — | WO | disclosed |
| US-20060047001-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | JANSSEN PHARMACAEUTICA N.V. (BE) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276528-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | GABRA5, SULT2A1, SYNGR2 | BACE1 175/4885POLB 4627/4885SMN1; SMN2 1687/4885 |
| US-20070191451-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | NLN, CTSA, SMN1; SMN2 | BACE1 39/4885POLB 4455/4885SMN1; SMN2 3/4885 |
| US-20060047001-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | GABRE, GABRB2, GABRA2 | BACE1 314/4885POLB 4666/4885SMN1; SMN2 1538/4885 |
| US-20070191459-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels | LIPC, GPR119, APOB | BACE1 1598/4885POLB 4027/4885SMN1; SMN2 3555/4885 |
| US-20070293476-A1 | CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | GABBR1, SYNGR2, GABBR2 | BACE1 453/4885POLB 4026/4885SMN1; SMN2 620/4885 |
| US-20070191452-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRL1, SULT2A1, OPRK1 | BACE1 2540/4885POLB 4610/4885SMN1; SMN2 781/4885 |
| US-20060270856-A1 | Process for preparation of sulfamide derivatives | STS, SULT2A1, SULT1A1 | BACE1 1681/4885POLB 4032/4885SMN1; SMN2 1997/4885 |
| US-20070191453-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | SULT2A1, SULT1A1, STS | BACE1 2422/4885POLB 3410/4885SMN1; SMN2 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.